Boosting HIV treatment options: Good news, new challenges

Journal of Infectious Diseases

Volumn 208, Issue 1, 2013, Pages 4-6

  Cahn, Pedro ^a   Sued, Omar ^a  

^a FUNDACIÓN HUÉSPED   (Argentina)

Author keywords

boosted PIs; cobicistat; pharmacoenhancer

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR; EMTRICITABINE; GENERIC DRUG; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR DISOPROXIL;

COMORBIDITY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE JAUNDICE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCOSURIA; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOPHOSPHATEMIA; JAUNDICE; KIDNEY FUNCTION TEST; KIDNEY TUBULE DISORDER; NAUSEA; NOTE; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; VOMITING;

BOOSTED PIS; COBICISTAT; PHARMACOENHANCER;

ADENINE; ANTI-HIV AGENTS; CARBAMATES; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PYRIDINES; RITONAVIR; THIAZOLES;

EID: 84878546354     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit124     Document Type: Note

References (15)

1. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010; 87:322-9.
2. Callebaut C, Tsai L, Stray K, et al. Biological profiling of GS-9350, a novel pharmacoenhancer that lacks anti-HIV activity and exhibits low potential for metabolic adverse effects in vitro. Antiviral Res 2010; 86:0-0.
3. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
4. DeJesus E, Rockstroh JK, Henry K, et al. Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429-38.
5. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012; 61:32-40.
6. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutesof the AntiviralDrugsAdvisoryCommittee Meeting, May 11, 2012. http://www. fda.gov/downloads/AdvisoryCommittees/Com mitteesMeetingMaterials/ Drugs/AntiviralDrug sAdvisoryCommittee/UCM313684.pdf. Accessed 30 January 2013.
7. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
8. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102-8.
9. Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 2012; 56:5409-13.
10. Callebaut C, Margot N, Stepan G, et al. Virological profiling of GS 7340, a next-generation tenofovir prodrug with superior potency over tenofovir DF [abstract H-522]. In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 9-12 September 2012.
11. NCT01780506: study to evaluate the safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in HIV-1 positive, antiretroviral treatment-näve adults. http://www.clinicaltrials. gov/ct2/show/NCT01780506. Accessed 30 January 2013.
12. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS 2011; 25:1881-6.
13. Gilead. Gilead submits new drug application to U.S. FDA for boosting agent cobicistat [media release]. 2012. http://www.gilead .com/pr-1710422. Accessed 30 January 2012.
14. Kakuda TN, Opsomer M, Timmers M, et al. Bioavility of two FDC formulations of darunavir/cobicistat 800/150mg compared with darunavir/ritonavir 800/100mg coadministered as single agents [abstract 020]. In: 13 International Workshop on Clinical Pharmacology of HIV therapy, Barcelona, Spain, April 2012.
15. Medicines Patent Pool. Stimulating Innovation EA, Improving Health. Annual Report 2010-2011, 2012. http://www.medicinesp atentpool.org/wp-content/ uploads/Medicin es-Patent-Pool-Annual-Report-2010-2011-Rev Final.pdf. Accessed 30 January 2013.